PMID- 37105716
OWN - NLM
STAT- MEDLINE
DCOM- 20230724
LR  - 20230724
IS  - 1535-2900 (Electronic)
IS  - 1079-2082 (Linking)
VI  - 80
IP  - 15
DP  - 2023 Jul 21
TI  - Infection risk and management strategies for patients with cirrhosis taking 
      proton pump inhibitors.
PG  - 967-973
LID - 10.1093/ajhp/zxad089 [doi]
AB  - PURPOSE: The purpose of this review is to discuss infectious disease-related 
      adverse effects associated with long-term proton pump inhibitor (PPI) therapy in 
      patients with cirrhosis and to provide recommendations for appropriate use and 
      choice of PPI when such therapy is indicated. SUMMARY: Long-term PPI therapy in 
      patients with cirrhosis increases the risk of infections, with infections in turn 
      increasing the risk of mortality in this patient population. Expert 
      recommendations include restricting long-term PPI use in cirrhosis to patients 
      with appropriate gastrointestinal indications, using a PPI for the shortest 
      possible duration and at the lowest possible dose, and avoiding PPIs with 
      unfavorable pharmacogenetic properties. CONCLUSION: Long-term PPI use in patients 
      with cirrhosis has been associated with increased infections. The risk of adverse 
      effects in observational studies, including decompensation, severe infection 
      (especially spontaneous bacterial peritonitis), and increased mortality, appears 
      to increase as the dose and duration of PPI increase.
CI  - (c) American Society of Health-System Pharmacists 2023. All rights reserved. For 
      permissions, please e-mail: journals.permissions@oup.com.
FAU - Zerr, Beth
AU  - Zerr B
AD  - Department of Pharmacy Practice and Science, University of Arizona R. Ken Coit 
      College of Pharmacy, Phoenix, AZ, USA.
FAU - Vazquez, Alejandro
AU  - Vazquez A
AD  - Department of Pharmacy Practice and Science, University of Arizona R. Ken Coit 
      College of Pharmacy, Phoenix, AZ, USA.
FAU - Erstad, Brian L
AU  - Erstad BL
AD  - Department of Pharmacy Practice and Science, University of Arizona R. Ken Coit 
      College of Pharmacy, Tucson, AZ, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Am J Health Syst Pharm
JT  - American journal of health-system pharmacy : AJHP : official journal of the 
      American Society of Health-System Pharmacists
JID - 9503023
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Humans
MH  - Proton Pump Inhibitors/adverse effects
MH  - *Bacterial Infections/drug therapy
MH  - Liver Cirrhosis/drug therapy/chemically induced/complications
MH  - *Peritonitis/drug therapy/epidemiology/complications
MH  - Risk Factors
OTO - NOTNLM
OT  - adverse effects
OT  - cirrhosis
OT  - complications
OT  - infectious disease
OT  - liver disease
OT  - proton pump inhibitors
EDAT- 2023/04/28 00:42
MHDA- 2023/07/24 06:42
CRDT- 2023/04/27 21:13
PHST- 2023/07/24 06:42 [medline]
PHST- 2023/04/28 00:42 [pubmed]
PHST- 2023/04/27 21:13 [entrez]
AID - 7146179 [pii]
AID - 10.1093/ajhp/zxad089 [doi]
PST - ppublish
SO  - Am J Health Syst Pharm. 2023 Jul 21;80(15):967-973. doi: 10.1093/ajhp/zxad089.